Blizzard Daniel J, Hills Christopher P, Isaacs Robert E, Brown Christopher R
Department of Orthopaedic Surgery, Duke University Medical Center, Post Office Box 3000, Durham, NC 27710, USA.
Department of Orthopaedic Surgery, Duke University Medical Center, Post Office Box 3000, Durham, NC 27710, USA.
J Clin Neurosci. 2015 Nov;22(11):1758-61. doi: 10.1016/j.jocn.2015.05.021. Epub 2015 Jun 29.
The purpose of this study was to evaluate our initial experience utilizing extreme lateral interbody fusion (XLIF; NuVasive, San Diego, CA, USA) with percutaneous posterior instrumentation to treat 11 spondylodiscitis patients between January 2011 and February 2014. Although medical management is the first line treatment for spondylodiscitis, many patients fail antibiotic therapy and bracing, or present with instability, neurologic deficits, or sepsis, requiring operative debridement and stabilization. High rates of fusion and infection clearance have been reported with anterior lumbar interbody fusion (ALIF), but this approach requires a morbid exposure, associated with non-trivial rates of vascular and peritoneal complications. XLIF is an increasingly popular interbody fusion technique which utilizes a fast and minimally invasive approach, sparing the anterior longitudinal ligament, and allowing sufficient visualization of the intervertebral discs and bodies to debride and place a large, lordotic cage. The outcome measures for this study included lumbar lordosis, sagittal balance, subsidence, fusion, pain, neurological deficit, and microbiology/laboratory evidence of infection. The mean follow-up time was 9.3 months. All patients had improvements in pain and neurological symptoms. The mean lordosis change was 11.0°, from 23.1° preoperatively to 34.0° postoperatively. Fusion was confirmed with CT scans in five of six patients. At the last follow-up, all patients had normalization of inflammatory markers, no symptoms of infection, and none required repeat surgical treatment for spondylodiscitis. XLIF with percutaneous posterior instrumentation is a minimally invasive technique with reduced morbidity for lumbar spine fusion which affords adequate exposure to the vertebral bodies and discs to aggressively debride necrotic and infected tissue. This study suggests that XLIF may be a safe and effective alternative to ALIF for the treatment of spondylodiscitis.
本研究的目的是评估我们在2011年1月至2014年2月期间,利用极外侧椎间融合术(XLIF;美国加利福尼亚州圣地亚哥市NuVasive公司)联合经皮后路内固定治疗11例腰椎间盘炎患者的初步经验。虽然药物治疗是腰椎间盘炎的一线治疗方法,但许多患者抗生素治疗和支具治疗失败,或出现不稳定、神经功能缺损或脓毒症,需要手术清创和稳定治疗。据报道,前路腰椎椎间融合术(ALIF)的融合率和感染清除率较高,但这种方法需要进行创伤较大的显露,且血管和腹膜并发症的发生率不低。XLIF是一种越来越受欢迎的椎间融合技术,它采用快速且微创的方法,保留前纵韧带,能够充分显露椎间盘和椎体,以便进行清创并置入一个大的前凸椎间融合器。本研究的结果指标包括腰椎前凸、矢状面平衡、下沉、融合、疼痛、神经功能缺损以及感染的微生物学/实验室证据。平均随访时间为9.3个月。所有患者的疼痛和神经症状均有改善。腰椎前凸平均变化为11.0°,从术前的23.1°增至术后的34.0°。6例患者中有5例经CT扫描证实融合。在最后一次随访时,所有患者的炎症指标均恢复正常,无感染症状,且无一例因腰椎间盘炎需要再次手术治疗。XLIF联合经皮后路内固定是一种微创技术,用于腰椎融合时发病率较低,能够充分显露椎体和椎间盘,以便积极清创坏死和感染组织。本研究表明,XLIF可能是治疗腰椎间盘炎的一种安全有效的替代ALIF的方法。